文献速递中医儿科中医内科中药与中成药合理使用

神曲消食口服液与多潘立酮糖浆治疗儿童功能性消化不良的疗效与安全性

Efficacy and Safety of Shenqu Xiaoshi Oral Liquid Compared With Domperidone Syrup in Children With Functional Dyspepsia.
PubMed 文献 · Front Pharmacol · 2022-02-04

本随机双盲双模拟非劣效多中心试验纳入356例3-14岁符合罗马IV标准的功能性消化不良患儿,比较神曲消食口服液与多潘立酮糖浆治疗2周的疗效。结果显示两组第2周临床应答率相似(83.10% vs 81.01%,差值2.09,95%CI -6.74至10.71),非劣效成立,且两组症状评分在1、2、4周均显著改善,不良事件轻微。

要点

  • 神曲消食口服液治疗2周对儿童FD的应答率非劣效于多潘立酮糖浆。
  • 两组FD症状总分在1、2、4周随访均较基线显著改善(p<0.005)。
  • 不良事件轻微,无严重不良事件,神曲消食口服液耐受性良好。

核心结论

  • 神曲消食口服液能有效改善儿童功能性消化不良症状且耐受性良好,疗效非劣效于多潘立酮糖浆,并带来持续改善。

研究设计与样本

  • 随机、双盲、双模拟、非劣效、多中心临床试验,纳入356例3-14岁符合罗马IV标准的功能性消化不良患儿,来自中国17家三级医疗中心,按1:1随机接受神曲消食口服液或多潘立酮糖浆治疗2周。

主要发现

  • 第2周临床应答率神曲消食口服液组为118/142(83.10%),多潘立酮组为128/158(81.01%),差值2.09,95%CI -6.74至10.71,非劣效成立。
  • 两组FD症状总分在1、2、4周随访均显著改善(p<0.005),且较基线的症状评分下降两组相似。
  • 研究期间共10例发生至少一次治疗相关不良事件,神曲消食口服液组6例(3.37%),多潘立酮组4例(2.25%),无严重不良事件。

关键数值与推荐

  • 主要终点为治疗2周结束时FD症状临床评分较基线下降≥30%的患者比例,非劣效界值为-10%。
  • 共评估373例患者,最终入组并随机356例。

临床怎么用

  • 对于3-14岁符合罗马IV标准的功能性消化不良患儿,可考虑使用神曲消食口服液治疗2周,其疗效不劣于多潘立酮糖浆且安全性良好。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Treatment of functional dyspepsia (FD) in children is generally symptomatic and unsatisfactory. Traditional Chinese medicines, such as Shenqu Xiaoshi Oral Liquid (SXOL), have been recommended to alleviate dyspeptic symptoms. However, evidence of their safety and efficacy remains limited to date. AIM: To assess whether 2 weeks of therapy with SXOL was non-inferior to domperidone syrup in children with FD. Methods: In this randomized, double-blind, double-simulated, non-inferiority, multi-center clinical trial, we recruited children (3-14 years) with FD according to the Rome IV criteria from 17 tertiary medical centers across China. Patients were randomly allocated (1:1) to receive SXOL or domperidone syrup for 2 weeks. We compared the participants' clinical scores from both groups based on the severity and frequency of dyspepsia symptoms according to Rome IV criteria (0, 1, 2, and 4 weeks after randomization). The primary endpoint was the total response rate, which was defined as the proportion of patients with a decrease of 30% or more in the FD symptoms clinical score from baseline, at the end of the 2-weeks treatment. A non-inferiority margin of -10% was set. Secondary endpoints and adverse events were assessed. This trial is registered with www.Chictr.org.cn, number ChiCTR1900022654. Results: Between February 2019 and March 2021, a total of 373 patients were assessed for eligibility, and 356 patients were enrolled and randomized. The clinical response rate at week two was similar for SXOL [118 (83.10%) of 142] and domperidone [128 (81.01%) of 158]; difference 2.09; 95% CI -6.74 to 10.71, thereby establishing non-inferiority. The total FD symptom scores were significantly improved in the two groups at 1-, 2-, and 4-weeks follow-up periods (p < 0.005). The decrease in symptom score compared with the baseline were similar between these two groups. Over the total study period, 10 patients experienced at least one treatment-related adverse event [six (3.37%)] in the SXOL group, four [(2.25%) in the domperidone group], although no serious adverse event was noted. Conclusion: Treatment with SXOL effectively improves dyspeptic symptoms and is well tolerated. In addition, it is not inferior to domperidone syrup and leads to sustained improvement in Chinese children with FD.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yu Y, Xie XL, Wu J, et al. Efficacy and Safety of Shenqu Xiaoshi Oral Liquid Compared With Domperidone Syrup in Children With Functional Dyspepsia. Front Pharmacol. 2022. PMID: 35185585. doi:10.3389/fphar.2022.831912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。